title: Reversible mitral and aortic regurgitation due to pioglitazone.
abstract: OBJECTIVE
  To report the occurrence of pioglitazone-induced reversible valvular regurgitant lesions.
  
  
  METHODS
  Clinical, laboratory, and imaging data are reported on a patient with known type 2 diabetes mellitus, who was prescribed pioglitazone to achieve better glycemic control.
  
  
  RESULTS
  We present a case report of a 50-year-old woman, in whom diabetes had been diagnosed 5 years previously, who developed severe mitral and aortic regurgitation during 5 months of treatment with pioglitazone along with clinical and laboratory indications of fluid retention. Echocardiography 5 months after discontinued use of pioglitazone showed regression of regurgitant lesions and normalization of pertinent laboratory variables.
  
  
  CONCLUSIONS
  Five months of treatment with pioglitazone could potentially induce major cardiac valvular dysfunction, which was reversible in our patient. This report emphasizes the importance of carefully monitoring patients during treatment with thiazolidinediones.
authors.affiliation: Department of Endocrinology, Medwin Hospitals, Hyderabad, Andhra Pradesh, India. hidocsunil@ibibo.com
authors.forename: Sunil K
authors.initials: SK
authors.lastname: Kota
authors.forename: Prabhas R
authors.initials: PR
authors.lastname: Tripathy
authors.forename: Siva K
authors.initials: SK
authors.lastname: Kota
authors.forename: Sruti
authors.initials: S
authors.lastname: Jammula
authors.forename: Sandip
authors.initials: S
authors.lastname: Panda
authors.forename: Kirtikumar D
authors.initials: KD
authors.lastname: Modi
mesh_terms: D001022:Aortic Valve Insufficiency / Q000139:chemically induced* / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000188:drug therapy; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D007004:Hypoglycemic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D008875:Middle Aged; D008944:Mitral Valve Insufficiency / Q000139:chemically induced* / Q000150:complications / Q000503:physiopathology / Q000628:therapy; D000077205:Pioglitazone; D011719:Pyrazines / Q000627:therapeutic use; D012720:Severity of Illness Index; D000068900:Sitagliptin Phosphate; D045162:Thiazolidinediones / Q000009:adverse effects* / Q000627:therapeutic use; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D007004:Hypoglycemic Agents; D011719:Pyrazines; D045162:Thiazolidinediones; D014230:Triazoles; D000068900:Sitagliptin Phosphate; D000077205:Pioglitazone